

88
90. The method of claim 88, wherein the effective amount is between about 0.01 and 0.6 mg/kg.

89
91. The method of claim 88, wherein the effective amount is between about 0.01 mg/kg and about 0.3 mg/kg.

90
92. The method of claim 88, wherein the effective amount is between about 0.4 mg/kg and about 0.8 mg/kg.

91
93. The method of claim 88, wherein the effective amount is between about 0.3 mg/kg and about 0.6 mg/kg.

92
94. The method of claim 88, wherein the cancer is a solid tumor.

93
95. The method of claim 88, wherein the cancer is breast cancer, melanoma, leukemia or ovarian cancer.

94
96. The method of claim 88, wherein the cancer is an MDR-resistant cancer.

REMARKS

As detailed above Applicants have amended claim 30, and have added claims 60-96. Claims 1-29 and 31-59 are also cancelled with this response and certain subject matter of original claims 1-8, 30-33, 45-58 (corresponding to the subject matter of Group II) is now incorporated into claim 30 and new claims 60-96. Applicants respectfully submit that no new matter is presented with these amendments or additions. Applicants have also submitted herewith a Supplemental Information Disclosure Statement and respectfully request that the Examiner consider the patents and applications cited therein.

Applicants would like to thank the Examiner in advance for review of this request. If it is believed that a telephone conversation would expedite matters, the Examiner is invited to contact

the undersigned at (617) 248-5216. The Examiner is authorized to charge any fees associated with this amendment, or to refund fees for any overpayment, to our Deposit Account No.: 03-1721

Respectfully submitted,

Karoline K. M. Shair

Karoline K. M. Shair, Ph.D.



Reg. No.: 44,332

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5216
Date: January 28, 2002
3359713_1.DOC


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231 on January 28, 2002
Steven E. Wespe

Marked-up Copy of Claim 30

30. A pharmaceutical composition for treating cancer comprising a compound [of claim 1, 3, 5, 7, or 8] and a pharmaceutically [suitable] acceptable carrier, wherein the compound has the structure:



; or



wherein R, R₀, and R' are independently H, linear or branched chain alkyl, optionally substituted by hydroxy, alkoxy, carboxy, carboxaldehyde, linear or branched alkyl or cyclic acetal, fluorine, NR₁R₂, N-hydroximino, or N-alkoxyimino, wherein R₁ and R₂ are independently H, phenyl, benzyl, linear or branched chain alkyl; wherein Z is O, N(OR₃) or N-NR₄R₅, wherein R₃, R₄ and R₅ are independently H or a linear or branched chain alkyl; and wherein n is 0, 1, 2, or 3.